CLAIMS:

1. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 25), or a pharmaceutically acceptable salt thereof.

2. The modified oligonucleotide of claim 1, which is a pharmaceutically acceptable salt comprising one or more cations selected from sodium, potassium, calcium, and magnesium.

3. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 25).

4. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation: $A_{es}T_{ks}T_{dz}G_{dz}T_{ds}{}^{m}C_{ds}A_{ds}T_{ds}{}^{m}C_{ds}A_{ds}{}^{m}C_{es}{}^{m}C_{es}A_{es}G_{ko}A_{es}A_{ks}A_{e}$ (SEQ ID NO: 25), wherein:

A = an adenine nucleobase,

^{m}C = a 5-methylcytosine nucleobase,

G = a guanine nucleobase,

T = a thymine nucleobase,

e = a 2'-MOE sugar moiety,

k = a cEt sugar moiety,

d = a 2'-deoxyribosyl sugar moiety,

s = a phosphorothioate internucleoside linkage,

z = a mesyl phosphoramidate internucleoside linkage, and

o = a phosphodiester internucleoside linkage.

5. The oligomeric compound of claim 4, wherein the oligomeric compound comprises a conjugate group or a terminal group.

6. The oligomeric compound of claim 4 or claim 5, wherein the modified oligonucleotide is a pharmaceutically acceptable salt.

7. The oligomeric compound of claim 6, comprising one or more cations selected from sodium, potassium, calcium, and magnesium.

8. An oligomeric compound according to the following chemical notation: $N^1_{es}T_{ks}T_{dz}G_{dz}T_{ds}{}^{m}C_{ds}A_{ds}T_{ds}{}^{m}C_{ds}A_{ds}{}^{m}C_{es}{}^{m}C_{es}A_{es}G_{ko}A_{es}A_{ks}N^2{}_e$ (SEQ ID NO: 27), wherein:

A = an adenine nucleobase,

^{m}C = a 5-methylcytosine nucleobase,

G = a guanine nucleobase,

T = a thymine nucleobase,

N^1 = an adenine nucleobase, a modified adenine, a hypoxanthine, an abasic sugar moiety, a terminal group, or is absent, wherein when N^1 is absent its sugar and internucleoside linkage are also absent,

N^2 = an adenine nucleobase, a modified adenine, a hypoxanthine, an abasic sugar moiety, a terminal group, or is absent, wherein when N^2 is absent its sugar is also absent,

e = a 2'-MOE sugar moiety,

k = a cEt sugar moiety,

d = a 2'-deoxyribosyl sugar moiety,

s = a phosphorothioate internucleoside linkage,

z = a mesyl phosphoramidate internucleoside linkage, and

o = a phosphodiester internucleoside linkage.

9. The oligomeric compound of claim 8, wherein the oligomeric compound comprises a conjugate group.

10. The oligomeric compound of claim 8 or claim 9, wherein:

a) N^1 is an adenine nucleobase and N^2 is an unmodified adenine, a hypoxanthine, an abasic sugar moiety, a terminal group, or is absent;

b) N^1 is a hypoxanthine and N^2 is an adenine nucleobase, an unmodified adenine, a hypoxanthine, an abasic sugar moiety, a terminal group, or is absent;

c) N^1 is absent and N^2 is an adenine nucleobase, an unmodified adenine, a hypoxanthine, an abasic sugar moiety, a terminal group, or is absent; or

d) N^1 is absent and N^2 is absent.

11. A population of modified oligonucleotides of any of claims 1-3 or a population of oligomeric compounds of any of claims 4-10, wherein all of the phosphorothioate internucleoside linkages of the modified oligonucleotide are stereorandom or all of the mesyl phosphoramidate internucleoside linkages of the modified oligonucleotide are stereorandom.

12. A pharmaceutical composition comprising a modified oligonucleotide of any of claims 1-3, an oligomeric compound of any of claims 4-10, a population of modified oligonucleotides of claim 11, or a population of oligomeric compounds of claim 11, and a pharmaceutically acceptable diluent.

13. The pharmaceutical composition of claim 13, wherein the pharmaceutically acceptable diluent is artificial cerebrospinal fluid (aCSF) or phosphate-buffered saline (PBS).

14. The pharmaceutical composition of claim 13, wherein the pharmaceutical composition consists essentially of:

a) the modified oligonucleotide and aCSF;

b) the oligomeric compound and aCSF;

c) the population of modified oligonucleotides and aCSF;

d) the population of oligomeric compounds and aCSF;

e) the modified oligonucleotide and PBS;

f) the oligomeric compound and PBS;

g) the population of modified oligonucleotides and PBS; or

h) the population of oligomeric compounds and PBS.

15. A modified oligonucleotide of any of claims 1-3, an oligomeric compound of any of claims 4-10, a population of modified oligonucleotides of claim 11, a population of oligomeric compounds of claim 11, or a pharmaceutical composition of any of claims 12-14 for use as a medicament.

16. The use according to claim 15, wherein the medicament is for reducing expression of HTT in a cell.

17. The use according to claim 16, wherein the cell is a human cell.

18. Use of a modified oligonucleotide of any of claims 1-3, an oligomeric compound of any of claims 4-10, a population of modified oligonucleotides of claim 11, a population of oligomeric compounds of claim 11, or a pharmaceutical composition of any of claims 12-14 for the manufacture of a medicament for treating Huntington's disease in a subject having or at risk of developing Huntington's disease.

19. The use according to claim 18, wherein at least one symptom or hallmark of Huntington's disease is ameliorated.

20. The use according to claim 19, wherein the symptom or hallmark is brain atrophy, muscle atrophy, nerve degeneration, uncontrolled movement, seizure, tremor, anxiety, memory lapse, or depression.